- Home
- JLS vs IMUX Comparison
JLS vs IMUX Comparison
Compare JLS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- IMUX
- Stock Information
- Founded
- JLS 2009
- IMUX 2016
- Country
- JLS United States
- IMUX United States
- Employees
- JLS N/A
- IMUX N/A
- Industry
- JLS Investment Managers
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- IMUX Health Care
- Exchange
- JLS Nasdaq
- IMUX Nasdaq
- Market Cap
- JLS 102.7M
- IMUX 86.3M
- IPO Year
- JLS N/A
- IMUX N/A
- Fundamental
- Price
- JLS $18.87
- IMUX $1.27
- Analyst Decision
- JLS
- IMUX Strong Buy
- Analyst Count
- JLS 0
- IMUX 6
- Target Price
- JLS N/A
- IMUX $12.67
- AVG Volume (30 Days)
- JLS 26.6K
- IMUX 795.3K
- Earning Date
- JLS 01-01-0001
- IMUX 03-04-2025
- Dividend Yield
- JLS 9.33%
- IMUX N/A
- EPS Growth
- JLS N/A
- IMUX N/A
- EPS
- JLS N/A
- IMUX N/A
- Revenue
- JLS N/A
- IMUX N/A
- Revenue This Year
- JLS N/A
- IMUX N/A
- Revenue Next Year
- JLS N/A
- IMUX N/A
- P/E Ratio
- JLS N/A
- IMUX N/A
- Revenue Growth
- JLS N/A
- IMUX N/A
- 52 Week Low
- JLS $15.48
- IMUX $0.92
- 52 Week High
- JLS $17.97
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- JLS 56.67
- IMUX 72.48
- Support Level
- JLS $18.75
- IMUX $0.92
- Resistance Level
- JLS $19.06
- IMUX $1.15
- Average True Range (ATR)
- JLS 0.16
- IMUX 0.07
- MACD
- JLS -0.02
- IMUX 0.03
- Stochastic Oscillator
- JLS 61.40
- IMUX 74.47
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The Fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.